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CEACAM1 splice variants in melanoma extracellular domains. Both isoforms are trans-membrane anchored and carry either the long (L, 73 aa) or short (S, 10 aa) cytoplasmic domain (27) .
CEACAM1 has been controversially discussed as tumor suppressor and driver of invasion (28, 29) . Most studies contributing to this discussion were focused on total CEACAM1 or CEACAM1-4L/S. In 2002, Thies and colleques showed that the CEACAM1 protein expression in primary cutaneous melanoma predicts the development of metastatic disease (30) . Furthermore, levels of soluble CEACAM1 in sera from melanoma patients have been shown to inversely correlate with overall survival (31, 32) . This spurred discussion of CEACAM1 as a more specific and sensitive biomarker than those currently used, including melan-A, S100β and HMB45, and has implicated CEACAM1 as a potential novel therapeutic target (14) .
Nevertheless, none of these studies addressed the impact of the four CEACAM1 splice variants.
Furthermore, the clinical impact and the precise mechanism by which the four CEACAM1 variants modulate melanoma progression is completely unknown. Our present study analyzed the biological function and clinical relevance of the individual CEACAM1 splice variants in human melanoma biopsies of increasing disease stages and in cell lines, established from patient's metastases. We show for the first time that CEACAM1-3S, CEACAM1-3L, CEACAM1-4S and CEACAM1-4L differentially impact cellular function and melanoma progression. Furthermore, we demonstrate that the expression of CEACAM1-3S correlates significantly with the clinical stage and strikingly with a prolonged patient overall survival. Finally, we provide strong evidences that CEACAM1-3S triggers melanoma cells for NK cell-mediated cytolysis by up-regulating cell surface expression of MICA and ULBP2, whereas CEACAM1-4L 6 CEACAM1 splice variants in melanoma causes the contrary effect due to enhanced shedding of both NKG2D ligands (NKG2DLs). Committee on Cancer (AJCC) (44) . Cell lines were established from malignant melanoma as described before (45, 46) . RPMI 1640 supplemented with 10% fetal calf serum (FCS), 1% Penicillin/Streptomycin and 1% L-Glutamine (all from PAA Laboratories) was used as culture medium. All cell lines were maintained at 37°C and 5% CO 2 and regularly tested for mycoplasma infection.
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Plasmid constructs and transfection
The coding sequences for CEACAM1-3L (NM_001184813.1), CEACAM1-3S (NM_001184816.1), CEACAM1-4L (NM_001712.4) and CEACAM1-4S (NM_001024912.2) were cloned into the pcDNA3.1(-) Neo plasmid (Invitrogen) and verified by sequencing. Constructs were transfected into the Ma-Mel-86a cell line using Metafectene (Biontex) according to manufacturer's protocol, and single clones selectively grown in medium containing 1mg/ml G418 (Carl Roth).
CEACAM1 splice variants in melanoma xCELLigence System
The Real-Time Cell Analyzer System was used to analyze cellular functions (47) and cytotoxicity (48) . The experiments were performed as described by manufacturer's instructions. In short, the half maximum cell index (CI 50 ) between 0 to 70 hours (CI 50 ) was used for determination of statistical differences calculated by Student's t-test.
Cytotoxicity results are presented as percentages of cytolysis determined from normalized cell index (nCI): % of specific lysis= [nCI(no effector)-nCI(effector)]/nCI(no effector) x100. Experiments were performed in duplicates.
Please refer to the detailed Supplemental Experimental Procedures.
Immunofluorescence
Melanoma cells on coverslips were grown to 90% confluency. Cells were fixed either with methanol or 4% PFA, blocked with 3% BSA/PBS, then incubated at 4°C overnight with primary antibodies in 1.5% BSA/PBS. Primary antibodies were visualized by fluorescent labed secondary antibodies. Nuclei were counterstained with DAPI (Carl Roth), and fluorescence microscopy was conducted on a Leica SP8 confocal microscope (Leica), Zeiss AxioObserver.Z1 with Apotome and Zeiss ELYRA PS.1 using SIM technology (Zeiss). Antibody information are provided in Supplementary Material and Methods section.
Flow cytometry
Surface expressions were analyzed using a FACScalibur flow cytometer and the CellQuest Pro software (BD Biosciences), Gallios system (Beckman Coulter) equipped with FlowJo software and Accuri C6 flow cytometer (BD Biosciences). Cells were harvested, incubated with primary antibodies and fluorescence conjugated 9 CEACAM1 splice variants in melanoma secondary antibodies. Isotype matched control antibody staining served as negative control. Dead cells were excluded from measurements by Propidium Iodide staining.
Antibody information are provided in Supplementary Material and Methods section.
MICA ELISA
Soluble MICA (sMICA) was quantified, using the DuoSet® ELISA Development System (R&D Systems) according to the to manufacturer´s protocol. Melanoma cells were starved for 24h. Supernatant. was collected and centrifuged to remove cellular debris. Levels of sMICA were normalized to cell number at time of harvesting. NK cells were cultured in the presence of 200 IU/ml IL-2 (Chiron) prior to analyses.
Enrichment of primary polyclonal NK cells
Facs-based cytotoxicity assay
To determine specific lysis of melanoma cells by NK cells flow cytometric analysis was performed (49) . In brief, melanoma cells (5x10 6 cells/ml) were labeled with 2 nM CFSE for 10 min (Invitrogen). . Then antibody pre-treated NK cells were added to 5x10 4 of CFSE-labeled melanoma cells at various effector to target ratios for 3 h. 7-AAD (Cayman Chemicals) was added to each sample according to manufacturer's protocol. Probes were measured directly in a Gallios flow cytometer (Beckman Coulter). Gating strategy was used as described in Heinemann et al., 2012 (49) . Time-to-event data (from melanoma diagnoses till death or the last observation in case of censoring) were displayed using the method of Kaplan-Meier. Given the problems of selecting an appropriate cut-off / cut point value which is often done data-driven, we decided to display our results for the "presence of any transcripts" in contrast to "no transcripts". Subgroups in Kaplan-Meier plots were compared using log-rank statistics; in addition, we used cox regression to the related estimate hazard ratio. All reported p-values are nominal and two-sided. We applied a significance level of 5% and did not adjust for multiple testing. Table S1 ).
Statistical analysis
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Results
Analysis
Next we assessed the impact of CEACAM1 splice variants during melanoma progression, by analyzing variant expression in 51 biopsies from melanoma patients that spanned stages I-IV according to the American Joint Committee on Cancer (AJCC). First, in 45 of 51 (88%) biopsies we observed CEACAM1 variant expression (Table 1, Supplementary Table S2) . Surprisingly, both CEACAM1-3 variants were absent in stage I/II melanomas, with only one exception that expressed CEACAM1-3L (Fig. 1A, Supplementary Table S2 ). CEACAM1-3S and CEACAM1-3L expression Table S2 ) and was significantly induced during early disease progression from stages I/II to stage III (p=0.030, Fig. 1A ). Moreover, CEACAM1-4L was either expressed alone or in combination with other isoforms, while no other isoform was expressed without CEACAM1-4L (Supplementary Table S2 ). In correspondence to our in vitro observations, CEACAM1-3S exhibit the lowest expression intensities while CEACAM1-4L was predominantly expressed ( and CEACAM1-4L did not affected the clinical outcome (data not shown).
CEACAM1 variants localize to different intracellular compartments in melanoma cells
To explore CEACAM1 isoform functionality, we stably transfected CEACAM1-3S, CEACAM1-3L, CEACAM1-4S or CEACAM1-4L, respectively, into the CEACAM negative cell line Ma-Mel-86a, established from a stage III metastases ( 14 CEACAM1 splice variants in melanoma CEACAM1-4L expression has been shown to enhance the migratory capacity and invasive potential of melanoma cells without affecting cell proliferation (13) . We found that expression of the different CEACAM1 isoforms transfected into Ma-Mel-86a did also not alter proliferation (data not shown). To investigate the specific contributions of each CEACAM1 isoform to cellular motility, we monitored the CEACAM1 transfectants in real time by using xCELLigence impedance measurement.
Expression of CEACAM1-4S (p=0.009) and CEACAM1-4L (p=0.025) had the strongest migration enhancing influence on melanoma cells, compared to control cells ( Fig. 4A and B) . Also CEACAM1-3L significantly increased migratory capacity, but to a lesser extent (p=0.023, Fig. 4A and B) . In accordance to this finding expression of CEACAM1-4S (p=0.006) and CEACAM1-4L (p=0.005) resulted in enhanced invasive behavior, which was only slightly increased by CEACAM1-3L ( transfectants was detected compared to control cells ( Fig. 6A and B) . Remarkably, expression of CEACAM1-4L resulted in damped cell surface expression of MICA (p=0.020) without affecting ULBP2 levels ( Fig. 6A and B) .
To verify if CEACAM1-3S indeed affected cell surface expression of NKG2D ligands, MICA and ULBP2 expression was determined by confocal microscopy. Expression of CEACAM1-3S resulted in enhanced recruitment of MICA and ULBP2 to the Ma-Mel86a-cell surface (Fig. 6C ). Parallel we analyzed ligand expression levels in the CEACAM1 transfectants using western blot. MICA and ULBP2 expression in wholecell lysates of CEACAM1-3L, CEACAM1-3S and CEACAM1-4S transfectants was consistent with the flow cytometric data (Fig. 6D) . Furthermore, we confirmed that CEACAM1-3S transfected cells upregulated MICA and ULBP2 expression (Fig. 6D) .
Unexpectedly, CEACAM1-4L expression did not alter the total protein expression of MICA and enhanced ULBP2 protein expression compared to control cells (Fig. 6D ).
These data did not correlate with our flow cytometric findings, unless the reduced MICA and ULBP2 surface levels in CEACAM1-4L positive cells would appear due to shedding. Accordingly, we examined the levels of soluble MICA (sMICA) and ULBP2 (sULBP2) in media conditioned by the CEACAM1 transfectants using western blot, 
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CEACAM1 splice variants in melanoma and exclusively detected enhanced amounts of sMICA and sULBP2 in conditioned medium obtained from CEACAM1-4L-expressing cells (Fig. 6E) . Quantification of sMICA by ELISA revealed an approximately 2-fold elevation (p=0.033) in conditioned medium from CEACAM1-4L-expressing cells compared to control cells (Fig. 6F) .
Noteworthy, Marimastat treatment reduced the level of soluble MICA (p=0.0034) to the control level (Fig. 6 G) .
Next we asked, whether the ~2-fold induction of MICA and ULBP2 on the surface of CEACAM1-3S-expressing cells would impact melanoma cell sensitivity to NK cellmediated recognition and cytolysis. Thus, the cytolytic activity of NK cells was measured by a CFSE/7-AAD cytotoxicity assay. As shown in Fig. 6H and 6I the sensitivity of CEACAM1-3S-expressing melanoma cells to NK cell-mediated cytolysis was proportional to MICA and ULBP2 cell surface expression. Cytolysis of CEACAM1-3S cells were significantly enhanced compared to control cells at an effector to target ratio of 10:1 (p=0.031, Fig. 6I ) with a corresponding outcome using a 5:1 ratio (data not shown). Blocking the NKG2D receptor by antibody significantly reduced NK cell-mediated cytolysis (control, p=0.0113; CEACAM1-3S, p=0.0085) compared to cultures to which isotype control antibody was added (Fig. 6I) .
To analyse whether the reduced MICA-surface level on CEACAM1-4L transfectants could dampen the NK cell-mediated killing we performed xCELLigence based cytotoxicity assays. Expression of CEACAM1-3S resulted in significant up-regulation of NK cell-mediated cytolysis compared to control transfectants ( Supplementary Fig.   S1A , p=0.0016). The specific lysis of control (p=0.0257) and CEACAM1-3S transfectants (p=0.0137) was reduced by blockage of NKG2D (Supplementary Fig.   S1A ). The expression of CEACAM1-4L revealed no significant modulatory effect although blockage of NKG2D significantly reduced cytolysis (p=0.0141, Supplementary Fig. S1A ). Nevertheless, data presented in Supplementary Fig. S1A are Fig. S2B ). First, 2h after NK cell addition (E/T=1:1) anti-NKG2D decreased the lysis of CEACAM1-3S transfectant (6.6%), and to lesser extend the vector control (1.7%). This confirmed our prior observation (Fig.6 H) . We observed similar effects utilizing anti-DNAM-1, resulting in reduced cytolysis of CEACAM1-3S (15%) and control (5.1%) transfectants under corresponding conditions. Nevertheless, simultaneous blockage of NKG2D and DNAM-1 resulted in synergistic effects and reduced the NK cellmediated lysis of both target cell lines to a comparable level (CEACAM1-3S: 26%; control: 21.6%, Supplementary Fig. S2B , 2h after NK cell addition, E/T=1:1). Interestingly, by selective expression of individual CEACAM1 isoforms in melanoma cells, we identified variant-specific cellular localizations that are determined by the extracellular domain. However, CEACAM1-4 variants were primarily membraneassociated, whereas CEACAM1-3 isoforms were predominantly localized in to vesicular-like structures that accumulated around the nucleus. Schumann et al. (41) has previously reported that CEACAM1-S binds to F-actin. Together with our data, this leads to the speculation that CEACAM1-3L-and CEACAM1-3S-positive vesicular structures move towards sites of cell-cell contact via association with actin fibers. No evidence currently exists in the literature to identify which specific motor proteins would mediate this process. Sadekova et al. described localization of CEACAM1 in lamellipodia, suggesting a potential role in cell motility (42) . However, it is still not understood if and how the extracellular domains of CEACAM1 affect downstream effectors, which modulate subsequently the localization of CEACAM1.
Early studies reported enhanced cell migration and invasion after transfection of CEACAM1-L into human melanoma cells, whereas, overexpression of the CEACAM1-S variant had no effect (13) . Contrary to this report, our data precisely show that CEACAM1-4L and CEACAM1-4S trigger the migratory capacity and invasive potential of melanoma cells, whereas CEACAM1-3S diminishes these cellular properties. In this context, Ebrahimnejad et al. has proposed that Tyr-488 within the ITIM domain of the CEACAM1 long cytoplasmic domain is essential for the invasive and migratory effect in CEACAM1-transfected melanoma cells (13) . The fact that our study show that the expression of CEACAM1-3L (also containing Tyr-488) influenced migratory and invasive potential less strongly than CEACAM1-4L and CEACAM1-4S, argues against the hypothesis. Moreover, the here shown 
surface, could result in stronger interaction with CEACAM1-4L on melanoma cells (Fig. 3 A) 
Figure 5
Enhanced invasiveness of CEACAM1-4S and CEACAM1-4L is mediated by MMPs. 
